Diabetes mellitus (DM) remains a significant global health challenge, contributing to high morbidity and mortality rates. In Indonesia, type 2 diabetes is increasing, with a substantial percentage of patients experiencing poor glycemic control. This study aims to explore the relationship between serum procalcitonin levels and fasting blood glucose (FBG) in patients with type 2 diabetes, assessing procalcitonin's potential as a biomarker for diabetes complications. A total of 122 patients with confirmed type 2 diabetes were included, excluding those with infection or recent trauma. Clinical parameters, including blood pressures, body mass index (BMI), and blood samples for FBG and procalcitonin levels, were collected. Statistical analysis was performed using SPSS version 26.0. The mean age of participants was 56.7 years, with 43.4% diagnosed with hypertension. A significant correlation was found between procalcitonin and FBG (p = 0.024, r = 0.205), indicating a weak positive relationship. No significant differences in procalcitonin levels were observed between hypertensive and non-hypertensive patients. The findings suggest that procalcitonin may serve as a useful biomarker in managing complications associated with type 2 diabetes. While the correlation with FBG was weak, the role of inflammation in diabetes progression highlights the need for further investigation. Integrating procalcitonin testing into clinical practice could enhance patient management, and future research should explore the mechanisms linking procalcitonin levels to diabetes complications, as well as establish reference values for procalcitonin in diabetic populations.
| Published in | International Journal of Diabetes and Endocrinology (Volume 9, Issue 4) |
| DOI | 10.11648/j.ijde.20240904.11 |
| Page(s) | 65-70 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Diabetes Mellitus, Fasting Blood Glucose, Procalcitonin
| [1] | Hossain, Md. J., Al-Mamun, Md., & Islam, Md. R. Diabetes Mellitus, The Fastest Growing Global Public Health Concern: Early Detection Should Be Focused. Health Science Reports. 2024, 7(3), e2004. |
| [2] | Hong, J., Surapaneni, A., Daya, N., Selvin, E., Coresh, J., Grams, M. E., et al. Retinopathy and Risk of Kidney Disease in Persons with Diabetes. Kidney Medicine. 2021, 3(5), 808-815. |
| [3] | Pamungkas, R. A., Chamroonsawasdi, K. Family Functional-based Coaching Program on Healthy Behavior for Glycemic Control among Indonesian Communities: A Quasi-experimental Study. Oman Medical Journal. 2020, 35(5), e173. |
| [4] | Oktora, S. I., Butar Butar, D. Determinants of Diabetes Mellitus Prevalence in Indonesia. Jurnal Kesehatan Masyarakat. 2022, 18(2), 266–73. |
| [5] | Purwanto, D. S., Mewo, Y. M., Kaligis, S. H. M., & Jim, E. L. Evaluation of Serum Ferritin in Type 2 Diabetes Mellitus: An Observational Study from North Sulawesi, Indonesia. International Journal of Diabetes and Endocrinology. 2022, 7(4), 103-108. |
| [6] | Lu, Y., Wang, W., Liu, J., Xie, M., Liu, Q., & Li, S. Vascular Complications of Diabetes: A Narrative Review. Medicine. 2023, 102(40), e35285. |
| [7] | Omar, J., Ahmad, N. S., Che-Soh, N. A. A., Wan-Azman, W. N., Yaacob, N. M., Abdul-Ghani, N. S., et al. Serum Procalcitonin (PCT) - Is there a Role as an Early Biomarker in Infected Diabetic Foot Ulcer (IDFU) Patients?. Malaysian Orthopaedic Journal. 2023, 17(2), 62-69. |
| [8] | Wang, Y., Shao, T., Wang, J., Huang, X., Deng, X., Cao, Y., et al. An Update on Potential Biomarkers for Diagnosing Diabetic Foot Ulcer at Early Stage. Biomedicine & Pharmacotherapy. 2021, 133, 110991. |
| [9] | Asirvatham, A., Menon, U., Pavithran, P., Vasukutty, J., Kumar, H., Bhavani, N., et al. Role of Procalcitonin as A Predictor of Clinical Outcome in Acute Diabetic Foot Infections: A Prospective Study. Indian Journal of Endocrinology and Metabolism. 2019, 23(1), 122-127. |
| [10] | Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., et al. Pathophysiology of Type 2 Diabetes Mellitus. International Journal of Molecular Sciences. 2020, 21(17), 6275. |
| [11] | Guan, H., Tian, J., Wang, Y., Niu, P., Zhang, Y., Zhang, Y., et al. Advances in Secondary Prevention Mechanisms of Macrovascular Complications in Type 2 Diabetes Mellitus Patients: A Comprehensive Review. European Journal of Medical Research. 2024, 29(1), 152. |
| [12] | Poznyak, A., Grechko, A. V., Poggio, P., Myasoedova, V. A., Alfieri, V., Orekhov, A. N. The Diabetes Mellitus–Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. International Journal of Molecular Sciences. 2020, 21(5), 1835. |
| [13] | Ahmed, H. H., Shousha, W. G., El Mezayen, H. A., Emara, I. A., Hassan, M. E. Clinical Significance of Procalcitonin and C-Reactive Protein in the Prediction of Cardiovascular Complications in Patients with Type 2 Diabetes Mellitus. Asian Journal of Pharmaceutical and Clinical Research. 2017, 10(9), 297-306. |
| [14] | Purwanto, D. S., Marunduh, S. R., Kaligis, S. H. M. Analysis of C-reactive Protein as an Inflammation Biomarker in Type-2 Diabetes Mellitus Patients at Minahasa, North Sulawesi, Indonesia. International Journal of Diabetes and Endocrinology. 2023, 8(4), 50-53 |
| [15] | Gonzalez, L. L., Garrie, K., Turner, M. D. Type 2 Diabetes – An Autoinflammatory Disease Driven by Metabolic Stress. Biochimica et Biophysica Acta - Molecular Basis of Disease. 2018, 1864(11), 3805–23. |
APA Style
Purwanto, D. S., Marunduh, S. R., Kaligis, S. H. M. (2024). Evaluation of Procalcitonin in Type-2 Diabetes Mellitus Patients in Minahasa, North Sulawesi, Indonesia. International Journal of Diabetes and Endocrinology, 9(4), 65-70. https://doi.org/10.11648/j.ijde.20240904.11
ACS Style
Purwanto, D. S.; Marunduh, S. R.; Kaligis, S. H. M. Evaluation of Procalcitonin in Type-2 Diabetes Mellitus Patients in Minahasa, North Sulawesi, Indonesia. Int. J. Diabetes Endocrinol. 2024, 9(4), 65-70. doi: 10.11648/j.ijde.20240904.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijde.20240904.11,
author = {Diana Shintawati Purwanto and Sylvia Ritta Marunduh and Stefana Helena Margaretha Kaligis},
title = {Evaluation of Procalcitonin in Type-2 Diabetes Mellitus Patients in Minahasa, North Sulawesi, Indonesia
},
journal = {International Journal of Diabetes and Endocrinology},
volume = {9},
number = {4},
pages = {65-70},
doi = {10.11648/j.ijde.20240904.11},
url = {https://doi.org/10.11648/j.ijde.20240904.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20240904.11},
abstract = {Diabetes mellitus (DM) remains a significant global health challenge, contributing to high morbidity and mortality rates. In Indonesia, type 2 diabetes is increasing, with a substantial percentage of patients experiencing poor glycemic control. This study aims to explore the relationship between serum procalcitonin levels and fasting blood glucose (FBG) in patients with type 2 diabetes, assessing procalcitonin's potential as a biomarker for diabetes complications. A total of 122 patients with confirmed type 2 diabetes were included, excluding those with infection or recent trauma. Clinical parameters, including blood pressures, body mass index (BMI), and blood samples for FBG and procalcitonin levels, were collected. Statistical analysis was performed using SPSS version 26.0. The mean age of participants was 56.7 years, with 43.4% diagnosed with hypertension. A significant correlation was found between procalcitonin and FBG (p = 0.024, r = 0.205), indicating a weak positive relationship. No significant differences in procalcitonin levels were observed between hypertensive and non-hypertensive patients. The findings suggest that procalcitonin may serve as a useful biomarker in managing complications associated with type 2 diabetes. While the correlation with FBG was weak, the role of inflammation in diabetes progression highlights the need for further investigation. Integrating procalcitonin testing into clinical practice could enhance patient management, and future research should explore the mechanisms linking procalcitonin levels to diabetes complications, as well as establish reference values for procalcitonin in diabetic populations.
},
year = {2024}
}
TY - JOUR T1 - Evaluation of Procalcitonin in Type-2 Diabetes Mellitus Patients in Minahasa, North Sulawesi, Indonesia AU - Diana Shintawati Purwanto AU - Sylvia Ritta Marunduh AU - Stefana Helena Margaretha Kaligis Y1 - 2024/11/12 PY - 2024 N1 - https://doi.org/10.11648/j.ijde.20240904.11 DO - 10.11648/j.ijde.20240904.11 T2 - International Journal of Diabetes and Endocrinology JF - International Journal of Diabetes and Endocrinology JO - International Journal of Diabetes and Endocrinology SP - 65 EP - 70 PB - Science Publishing Group SN - 2640-1371 UR - https://doi.org/10.11648/j.ijde.20240904.11 AB - Diabetes mellitus (DM) remains a significant global health challenge, contributing to high morbidity and mortality rates. In Indonesia, type 2 diabetes is increasing, with a substantial percentage of patients experiencing poor glycemic control. This study aims to explore the relationship between serum procalcitonin levels and fasting blood glucose (FBG) in patients with type 2 diabetes, assessing procalcitonin's potential as a biomarker for diabetes complications. A total of 122 patients with confirmed type 2 diabetes were included, excluding those with infection or recent trauma. Clinical parameters, including blood pressures, body mass index (BMI), and blood samples for FBG and procalcitonin levels, were collected. Statistical analysis was performed using SPSS version 26.0. The mean age of participants was 56.7 years, with 43.4% diagnosed with hypertension. A significant correlation was found between procalcitonin and FBG (p = 0.024, r = 0.205), indicating a weak positive relationship. No significant differences in procalcitonin levels were observed between hypertensive and non-hypertensive patients. The findings suggest that procalcitonin may serve as a useful biomarker in managing complications associated with type 2 diabetes. While the correlation with FBG was weak, the role of inflammation in diabetes progression highlights the need for further investigation. Integrating procalcitonin testing into clinical practice could enhance patient management, and future research should explore the mechanisms linking procalcitonin levels to diabetes complications, as well as establish reference values for procalcitonin in diabetic populations. VL - 9 IS - 4 ER -
Department of Biochemistry, Faculty of Medicine, Sam Ratulangi University, Manado, Indonesia; Department of Clinical Laboratory, R. D Kandou Central General Hospital, Manado, Indonesia
Department of Physiology, Faculty of Medicine, Sam Ratulangi University, Manado, Indonesia
Department of Biochemistry, Faculty of Medicine, Sam Ratulangi University, Manado, Indone
Information